Member Info for jmfw

Computer909. He sold out? He liquidated all of his holding? Where did you get that info?

Moniman's correct, Avacta is seen by many as a one trick pony.
Obviously all those who feel that way have done absolutely no research AND they didn't read the rns which also referred to ava6000.

Thanks Cest la Vie. Found answer to my question.

Perdita Barran states "So, back to @OfficialUoM
.. our pilot a rapid response, and for MassSpec, we are using a method that deactivates the virus after swab, which was not in the supply chain. "
Can anyone confirm that our test uses a method that deactivates the virus after swab?

We've no notification of tech t'fer so can it be ours? Like all other holders, really hope so, but will wait with bated breath (not too long I hope) for 'official' news.

From the Sharebuyers interview published 27 October "This is clearly a value driver of a scale that may only happen once in a lifetime and Avacta is working with world-class lateral flow test developers and manufacturers to harness the Affimer reagents that work so well in the ELISA test to create a rapid saliva-based coronavirus test as soon as possible."
Unless we have the pregnancy style saliva test developed by Cytiva there can be no tech to transfer! And, too many consequential imponderables.

If ours, it could be they need to test against the various different manufacturers ms machines currently in situ. It is supposed to be of use across all/most platforms. Consequence, 20k tests insufficient.
Also, we're not the only new (ms) tech on the block that has something of interest that needs to go through the test mill.

@whimax Unfortunately, the journey of the sp does not make sense (to me). It certainly was overvalued at £3, but even without Accustem current sp looks very oversold. I feel the ADR & Accustem events were handled poorly. I think by & large Tils is way, way under the radar, being only appreciated by the handful of very substantial investors (there until the end game) & larger group of much smaller investors (far more volatile). The (relatively) small amount of shares in public hands offers a leveraged opportunity for manipulation (by whom?) which I think we are seeing. Very much a case of the 'tail wagging the dog'.
Could easily be completely wrong. Hopefully we'll see this unsettling trend/sentiment reversed with conviction by the year.

Seems to be in complete control on Nasdaq. The shorting interest yesterday was an extraordinary 39%. While remaining mid/long term optimistic I would certainly hesitate to invest any/further funds until something really positive emerges.

@Poundcake - from rns 22July
Adeptrix's novel BAMS platform uses Affimer reagents to capture the virus and viral proteins from patient samples and combines this with the power of mass-spectrometry analysis to provide a highly sensitive and specific diagnostic test. Up to 1,000 nasopharyngeal swab or saliva samples per day can be analysed by a single technician using the BAMS assay, making it a very attractive high throughput technique for COVID-19 screening in the clinical setting.

@busymum. Think your post @ 8:49 a tad risque for the morning. Ok for post evening watershed.

The above coy is listed as a new holder of some 192k+ shares as at 30 Sept.
According to WikiP " It is one of the largest asset management companies in the world with US$2.511 trillion under management and US$31.62 trillion under custody and administration. It is the second largest custodian bank in the world."
Be surprised if they have invested on a whim.

for info, extract from an iweb notification I received recently
"Subsequently, the Demerger is expected to become effective on 30th October 2020 and the Ex-entitlement for the New Accustem shares is expected to be 2nd November 2020. However, it is not yet known when the New Accustem shares will be received. "

& may be another reason to demerge accustem from tils

Will be interesting to see how tils performs today in usa. Shorts were about 24% of volume on friday, & closing price was about £1.46. On VERY little volume pre-market is still about that level.

Innova's offering is owned by Pasaca: https://pasacacapital.com/ with numerous interests including Finance, Infrastruture, Manufacturing, Hi Tech, Entertainment & Healthcare. A partner in that organisation Ersin Sanft, co-founded Innova Strategies in 2017 (own Innova tried & tested??). Innova Strategies HQ is in Sri Lanka. Links to Pasaca & Innova's test....
https://pasacacapital.com/
https://static1.squarespace.com/static/5e8444f9372f7161749366af/t/5f252b2cb71b7012a5403a0f/1596271422787/TriedandTested+Rapid+Antigen+Test+v2.0.pdf
,

JP Morgan developed an 'algo bot' in 2017 (https://wccftech.com/jp-morgan-working-on-machine-learning-trading-bot/).
JPMorgan is Depositary Bank for the ADR Program.
Morgan Stanley hold a (small) position in tils as at 30 Jun
Common factor JPM.
Approx 18% short again yesterday, total short some 741k as at 15 October.
Something untoward??

Whimax, thought the value per share to be attributable at the time of the demerger &, therefore, that would be what the shorter has to pay the owner of the borrowed shares at that moment in time. Theoretically (don't for one minute suggest likely), if the Accustem valuation went down, the owner would have benefitted from a 'premium' payment. So, if value is established/paid at time of demerger In the event Accustem was sold, the owner of the borrowed shares would have no further rights.
I accept, the above is unlikely, but does anyone know for sure how shorting works in the current circumstance. I know shorters have to pay over dividends declared should they be short through to an ex-divi date, so using that as a guide hypothisised accordingly. Re any other news, yes that can happen at any time, but the shorters are ignoring that anyway.

In the highly unlikely event I was correct there would be a benefit to holders at the time of the split. The shorters shares would no longer exist which would mean the remaining shares increase in value.

Hopefully, failing the above, we should expect a mad scramble to close positions.

Y-Alam think the problem with the sp has been the Nasdaq listing & the adr in particular. There are other coys on AIM with multi billion £ potentential that have been at the mercy of mms, traders, etc that will only realise true value when products are validated/brought to market/bought out, that have suffered similarly to Tils (I also hold avct). Proof of the pudding will (hopefully) be Foralumab.

Whimax, I have wondered what value will be attributed to Accustem at the point of the demerger. If it is the current book value then I can see no reason why the shorters won't continue to hold through to the ex date 2 Nov. They could even continue to short until a 'true' valuation is established/notified, or news (or anticipated news) on Foralumab. Any opinion?